Irbesartan, a drug of this class, belongs to angiotensin II receptor blocker and is widely used in the treatment of many kidney diseases, such as diabetic nephropathy, IgA nephropathy, membranous nephropathy and so on. It has the effect of reducing proteinuria and has the effect of delaying the progression of renal function. For patients with renal insufficiency, it is currently advocated that it should not be used above 3mg/dl because of the risk of elevated blood creatinine and high potassium, and it can be tried to start with a small dose for patients below 3mg/dl, monitor blood creatinine and potassium, and gradually increase the dosage if there is no adverse reaction. In addition, patients with bilateral renal artery stenosis and the elderly should be more cautious when using.